FDA rare-disease regulatory "right-shift"
FDA rare-disease regulatory "right-shift"
One-line summary: A post-DOGE FDA appears to be lowering the efficacy bar for orphan/rare-disease programs — accepting filings on trials that missed endpoints — but the same agency is "decimated," making the posture a source of both upside optionality and unpredictability.
The insight
Through mid-2026 the FDA has signalled openness to rare/orphan approvals that would previously have been rejected: Agios' mitapivat was accepted for priority review in sickle cell despite missing its co-primary VOC endpoint, with no advisory committee required. Read as a posture, this shifts the probability-of-success distribution to the right for a whole class of previously-left-for-dead rare-disease names. The countervailing force is capacity: DOGE cuts and senior departures (Verdun, Marks) mean the agency is less able to "just get it right," and the walk-back of CRL transparency (no complete-response letters released since April) removes the investor information edge on exactly these decisions. So the right-shift is real but noisy — an options-like tailwind on a basket, not a reliable per-name catalyst.
Evidence
- eric-schmidt in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: "So if anyone needed any sign or signal that the FDA is open for business with regard to pretty much seems any orphan or rare disease opportunity, here it is yet again."
- matt-herper in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: "We're dealing with an FDA that's really been decimated and has lost a lot of seasoned people. And that makes it a lot harder to be, instead of lax or tough, just get it right."
- josh-schimmer in 2026-07-10-podcast-biotech-hangout-episode-188-july-10-2026: (on Duchenne precedent) "I think one could have argued around some of the Duchenne therapies that they actually did offer more harm than benefit because the data package was really not compelling at all."
The chain
Post-DOGE FDA lowers the rare-disease efficacy bar → probability-of-success re-rates for missed-endpoint refiles → long the rare-disease refile basket (AGIO/REPL, lateral QURE/SRPT/RGNX). Canonical: fda-right-shift-to-rare-disease-refile-rerate.
Contradictions / tensions
- Leniency vs. capacity: a decimated FDA may be erratic, not reliably lenient — the tailwind could reverse on a single high-profile rejection.
- CRL-transparency walk-back cuts investor visibility into how the agency is actually deciding.
Open questions
- Is the right-shift program-specific (Agios) or a durable posture that generalizes across the orphan/rare-disease pipeline?